Antibody Responses to Antigenic Sites 1 and 3 of Serotype 3 Poliovirus after Vaccination with Oral Live Attenuated or Inactivated Poliovirus Vaccine and after Natural Exposure

Herremans, Tineke; Reimerink, Johan; Kimman, Tjeerd G.; Avoort, H. G. A. M. Van Der

doi:10.1128/cdli.7.1.40-44.2000

Cited by 22 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,3 However, the immunological effect achieved by the inactivated poliovirus vaccine in children requires large amounts of antigen and a proper immunization schedule, which has been improved continuously since its application in the 1990s. 4 The global action plan for poliomyelitis eradication that was drafted by the World Health Organization (WHO) recommended using the inactivated poliovirus vaccine of the Sabin strain (sIPV) in developing countries; however, concerns were raised regarding the immune patterns of sIPV, and intradermal inoculation was suggested to achieve better immune effects with smaller amounts of antigen. 5,6 In fact, some data on intradermal immunization with IPV were positive and indicated that immunological studies would be useful for the development of novel inactivated enterovirus vaccines.…”

Section: Introductionmentioning

confidence: 99%

Role of innate lymphoid cells and dendritic cells in intradermal immunization of the enterovirus antigen

et al. 2019

View full text Add to dashboard Cite

Enterovirus type 71 (EV71) and coxsackievirus A 16 (CA16) are the major pathogens of human hand, foot, and mouth disease (HFMD). In our previous study, intramuscular immunization with the inactivated EV71 vaccine elicited effective immunity, while immunization with the inactivated CA16 vaccine did not. In this report, we focused on innate immune responses elicited by inactivated EV71 and CA16 antigens administered intradermally or intramuscularly. The distributions of the EV71 and CA16 antigens administered intradermally or intramuscularly were not obviously different, but the antigens were detected for a shorter period of time when administered intradermally. The expression levels of NF-κB pathway signaling molecules, which were identified as being capable of activating DCs, ILCs, and T cells, were higher in the intradermal group than in the intramuscular group. Antibodies for the EV71 and CA16 antigens colocalized with ILCs and DCs in skin and muscle tissues under fluorescence microscopy. Interestingly, ILC colocalization decreased over time, while DC colocalization increased over time. ELISpot analysis showed that coordination between DCs and ILCs contributed to successful adaptive immunity against vaccine antigens in the skin. EV71 and/or CA16 antigen immunization via the intradermal route was more capable of significantly increasing neutralizing antibody titers and activating specific T cell responses than immunization via the intramuscular route. Furthermore, neonatal mice born to mothers immunized with the EV71 and CA16 antigens were 100% protected against wild-type EV71 or CA16 viral challenge. Together, our results provide new insights into the development of vaccines for HFMD.

show abstract

Section: Introductionmentioning

confidence: 99%

Role of innate lymphoid cells and dendritic cells in intradermal immunization of the enterovirus antigen

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Interestingly, the lowest amount of antibody against site 1 was detected in O 1 K-vaccinated cattle; this could be due to the small sample size for this vaccine or because these five cattle were the only animals that received a booster dose on day 21 following vaccination. Herremans et al (2000) also observed a change in site-specific dominance associated with booster vaccination, finding a relative rise in the level of antibody to site 3 in poliovirus. In the case of the O 1 BFS group, 9 % of animals had approximately equal levels of antibodies against sites 1 and 2 ().…”

Section: Full Textmentioning

confidence: 80%

Foot-and-mouth disease virus epitope dominance in the antibody response of vaccinated animals

Mahapatra

Hamblin

Paton

2012

Journal of General Virology

View full text Add to dashboard Cite

Five neutralizing antigenic sites have been identified on the surface of serotype O foot-and-mouth disease virus (FMDV). A set of mAb neutralization-escape mutant viruses was used for the first time to evaluate the relative use of known binding sites by polyclonal antibodies from three target species: cattle, sheep and pigs. Antibodies to all five neutralizing antigenic sites were detected in all three species, with most antibodies directed against antigenic site 2, followed by antigenic site 1. In 76 % of cattle, 65 % of sheep and 58 % of pigs, most antibodies were directed against site 2. Antibodies specific to antigenic sites 3, 4 and 5 were found to be minor constituents in the sera of each of the target species. This implies that antigenic site 2 is a dominant neutralization immunogenic site in serotype O FMDV and may therefore be a good candidate for designing novel vaccines.Foot-and-mouth disease (FMD) is a severe, clinically acute vesicular disease of cloven-hoofed domestic and wild animals and is present in all continents except Australasia and North America. The causative agent of FMD is Footand-mouth disease virus (FMDV), the prototype member of the genus Aphthovirus in the family Picornaviridae. There are seven distinct serotypes of FMDV (O, A, C, Asia-1, SAT-1, SAT-2 and SAT-3) and multiple strains, indicating significant antigenic variability. Currently, immunization with conventional inactivated whole-virus vaccine is the main method of FMD control, but strain composition of vaccines must be selected with care. The humoral immune response has been generally accepted as the most important factor in conferring vaccine-induced protection against the disease, as a strong correlation has been reported between the levels of virus-neutralizing antibody produced after vaccination and subsequent protection of cattle, one of the main target species (Pay & Hingley, 1987). The mechanism by which antibodies protect against FMDV is poorly understood, and different factors may be involved in vivo compared with the situation measured in vitro (Dunn et al., 1998;McCullough et al., 1992). Several studies have been carried out in the last two decades to identify the targets on the virus surface for the binding of neutralizing antibodies, and mAbs have been powerful tools for identifying the amino acid footprint of different antigenic sites, mainly by sequencing mAb-resistant (mar) mutants. This approach has been used successfully to delineate the neutralizing antigenic sites of viruses representing serotypes O (Aktas & Samuel, 2000;Barnett et al., 1998;Crowther et al., 1993b), A (Baxt et al., 1989;Bolwell et al., 1989;Mahapatra et al., 2011;Thomas et al., 1988a), C (Mateu et al., 1990, Asia-1 (Grazioli et al., 2003) and SAT (Crowther et al., 1993a; Grazioli et al., 2006). FMDV serotype O is the most prevalent globally and has been studied most extensively. Five neutralizing antigenic sites (1-5), involving three of the capsid proteins (VP1-3), have been identified on the surface of serotype O FMDV (Aktas & Samue...

show abstract

“…IPV has also been used in supplementary immunization activity (SIA) to control outbreaks and accelerate poliovirus eradication in endemic countries [ 11 , 12 ]. Vaccination with only IPV was apparently inferior as measured by fecal shedding after challenge, but reportedly had different outcome when administered subsequent to doses of OPV [ 13 , 14 , 15 ]. Although many of these studies support the use of IPV after OPV, the timing of IPV and the effect of it on mucosal protection represented a knowledge gap.…”

Section: Introductionmentioning

confidence: 99%

Comparison of IPV to tOPV week 39 boost of primary OPV vaccination in Indian infants: an open labelled randomized controlled trial

Kanungo

Kim

Haldar

et al. 2017

Heliyon

View full text Add to dashboard Cite

BackgroundThe final endgame strategy of global polio eradication initiative includes switching from trivalent oral poliovirus vaccines (tOPV) to bivalent oral polio vaccine (bOPV), and introduction of inactivated poliovirus vaccine (IPV). This study compares IPV with tOPV week 39 boost in Indian infants.MethodsStarting 28 March 2012, we enrolled 372 Indian infant-mother pairs from Kolkata, India in an open-label, block-randomized, controlled trial comparing a 39 week tOPV to an IPV boost among infants immunized with three doses of tOPV. The primary outcome was mucosal immunity to poliovirus as measured by fecal polio virus shedding after OPV challenge. The secondary outcome was humoral response as defined by >1:8 titers for neutralizing antibodies at week 40. Seroconversion was measured by change in level of antibody titers from week 18 to week 40. The analyses were performed by both intention-to-treat (ITT) and per-protocol (PP) comparing the occurrences of outcomes between the arms of the study.FindingsBoth the study arms provided equivalent mucosal immunity at 52 weeks with a total shedding prevalence of 28%. Vaccination with IPV resulted in significantly higher seroconversion rates for Polio type 2 (p = 0.03) and Polio type 3 (p < 0.01).ConclusionsThis study indicates that an IPV boost at week 39 is equivalent to tOPV in intestinal immunity, and provides higher seroconversion compared to tOPV. The major limitation of the study was the additional OPV doses receive by infants during pulse polio immunization resulted in additional mucosal boosting, diminishing the impact of IPV or tOPV boost at week 39. However, IPV for OPV boost should prove to be a step forward in the global polio eradication initiative to reduce the problem of circulating vaccine-derived poliovirus (cVDPV).

show abstract

Antibody Responses to Antigenic Sites 1 and 3 of Serotype 3 Poliovirus after Vaccination with Oral Live Attenuated or Inactivated Poliovirus Vaccine and after Natural Exposure

Cited by 22 publications

References 28 publications

Role of innate lymphoid cells and dendritic cells in intradermal immunization of the enterovirus antigen

Role of innate lymphoid cells and dendritic cells in intradermal immunization of the enterovirus antigen

Foot-and-mouth disease virus epitope dominance in the antibody response of vaccinated animals

Comparison of IPV to tOPV week 39 boost of primary OPV vaccination in Indian infants: an open labelled randomized controlled trial

Contact Info

Product

Resources

About